We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
MB, you have spent all day on their board sometimes. I don't know if you have noticed but no-one has been successfully confirmed amongst new generation tests yet. ODX won't agree anything unless it works for them financially obviously. The article said they will be selling in the US too.
MB its irrelevant, we have NOT stopped any manufacturing to make space for what might come from AVCT.
How is that a bad thing?
Tricky what i said about Avacta is fairly accurate in terms of where they are in the process and the risk to the downside at the mcap, and the fact that Affimers have never led to a commercial product. I wouldn't say i have spent a lot of time, just given my honest view. Having watched the presentation today and read the results it has only validated my opinions.
Whether you think Avacta will be successful or not, the point is we already have much more exciting products that we will commercialise. How can you get excited about a tie up with a product that is yet to go through clinical trials that at best we might get 30% margin on if we directed our capacity to, when we have products we can make 50% minimum margin on? To put in layman's terms, why would i use 1m capacity to manufacture a test for Avactas to sell, when i can make my own test instead and sell it.
People put Avacta on a pedestal like they have every achieved anything, well they have not and until they have it will only be speculative. Mologic on the other hand have proven track record with a product already used in a Heathrow trial
I can't understand the negativity here either. It's ludicrous. MB has spent a lot of time undermining AVCT (on their board/) so I guess he's in denial. Because if/when this is confirmed he may feel a little bit embarrassed or even owe an apology to AVCT investors?
Symbo1 guess what? The stock exchange is very much made of hopes! That's what investment in high growth companies is all about. AVCT are credible. It's silly to say otherwise. They have a £300 million investment from a very large pharma, Cyvicta. We don't know if the government's 'pregnancy style testing kit' is one of our's or AVCT's. But now we are covered either way! The delays are starting to make me think it could be AVCT's. They have been focusing on developing and manufacturing the reagents for a good while. Reagents are the critical material that we are short of -one of the problems causing hold ups alongside the time involved in processing lab tests. All good that we are squarely on their radar. We can manufacture according to demand. The fact that we have more partnerships puts us in a better negotiating position for our price to some extent. The zone of manoeuvre on price is limited because we aren't the only manufacturer in the world. GLA!